Murphy Middleton Hinkle & Parker’s Bristol-Myers Squibb BMY Stock Holding History

Murphy Middleton Hinkle & Parker’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$461K	Hold	8,007	–	–	0.19%	100
2026 Q1	$486K	Buy	+8,007	New	+$467K	0.23%	94
2025 Q4	–	Sell	-8,207	Closed	-$370K	–	143
2025 Q3	$370K	Buy	8,207 +62	+0.8%	+$2.9K	0.18%	105
2025 Q2	$497K	Hold	8,145	–	–	0.28%	90
2025 Q1	$497K	Hold	8,145	–	–	0.28%	90
2024 Q4	$461K	Hold	8,145	–	–	0.26%	94
2024 Q3	$421K	Sell	8,145 -333	-4%	-$15.6K	0.23%	101
2024 Q2	$352K	Hold	8,478	–	–	0.2%	106
2024 Q1	$460K	Sell	8,478 -179	-2%	-$9.12K	0.27%	96
2023 Q4	$444K	Hold	8,657	–	–	0.27%	90
2023 Q3	$502K	Hold	8,657	–	–	0.32%	82
2023 Q2	$554K	Hold	8,657	–	–	0.35%	82
2023 Q1	$600K	Buy	8,657 +333	+4%	+$23.5K	0.37%	79
2022 Q4	$599K	Hold	8,324	–	–	0.38%	77
2022 Q3	$592K	Buy	8,324 +3	+0%	+$218	0.41%	76
2022 Q2	$641K	Hold	8,321	–	–	0.42%	78
2022 Q1	$608K	Sell	8,321 -60	-0.7%	-$4.03K	0.33%	85
2021 Q4	$523K	Hold	8,381	–	–	0.28%	89
2021 Q3	$496K	Hold	8,381	–	–	0.29%	91
2021 Q2	$560K	Buy	8,381 +134	+2%	+$8.74K	0.31%	87
2021 Q1	$521K	Hold	8,247	–	–	0.3%	87
2020 Q4	$512K	Sell	8,247 -460	-5%	-$28.3K	0.34%	82
2020 Q3	$525K	Hold	8,707	–	–	0.38%	79
2020 Q2	$512K	Buy	8,707 +9	+0.1%	+$538	0.38%	81
2020 Q1	$485K	Sell	8,698 -115	-1%	-$7.03K	0.43%	73
2019 Q4	$566K	Buy	8,813 +1,680	+24%	+$96.2K	0.38%	76
2019 Q3	$362K	Hold	7,133	–	–	0.26%	92
2019 Q2	$323K	Buy	7,133 +175	+3%	+$8.15K	0.23%	99
2019 Q1	$332K	Hold	6,958	–	–	0.23%	100
2018 Q4	$362K	Hold	6,958	–	–	0.28%	90
2018 Q3	$432K	Buy	6,958 +200	+3%	+$11.9K	0.31%	87
2018 Q2	$374K	Sell	6,758 -48	-0.7%	-$2.59K	0.28%	91
2018 Q1	$430K	Sell	6,806 -115	-2%	-$7.4K	0.33%	80
2017 Q4	$424K	Buy	+6,921	New	+$433K	0.32%	81

Other funds holding BMY

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

AIM

Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

FWIA

Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

DLA

Douglas Lane & Associates New York $7.37B AUM 21.9% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Asset Management One Tokyo, Japan $39B AUM 37.51% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Murphy Middleton Hinkle & Parker's BMY Position: Q2 2026 in Review

Murphy Middleton Hinkle & Parker held its Bristol-Myers Squibb (BMY) position steady in Q2 2026 at 8,007 shares worth $461K. The position accounts for 0.19% of the portfolio, ranked #100.

Murphy Middleton Hinkle & Parker first reported a position in BMY in Q4 2017 and has held it in 34 quarters since. The position peaked at $641K in Q2 2022. 887 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

Murphy Middleton Hinkle & Parker held 8,007 shares of Bristol-Myers Squibb worth $461K as of Q2 2026.
Murphy Middleton Hinkle & Parker left its Bristol-Myers Squibb share count unchanged in Q2 2026.
Bristol-Myers Squibb made up 0.19% of Murphy Middleton Hinkle & Parker's portfolio in Q2 2026, its #100 holding.
Murphy Middleton Hinkle & Parker first reported a position in Bristol-Myers Squibb in Q4 2017 and has held it in 34 quarters since.
Murphy Middleton Hinkle & Parker's Bristol-Myers Squibb position peaked at $641K in Q2 2022.
887 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Murphy Middleton Hinkle & Parker's 13F filing for Q2 2026, filed 14 Jul 2026.